The writing committee decided on this approach for 2 reasons. First, in patients with acute coronary syndromes, abundant data indicate that revascularization with PCI is bene cial, and prior measure sets focused on this disease condition have included measures targeting these patients (e.g., door-to-balloon time in ST-elevation myocardial infarction). Second, in selected patients un- dergoing elective procedures, such as those with chronic stable angina, there is greater controversy as to the best therapy that should be used. Patients referred to the cardiac catheterization laboratory in these settings usually have stable angina that is no longer controlled with medications or have high-risk ndings on a noninvasive stress test. The bene t of PCI in these patients is pri- marily symptom reduction, and data on a mortality rate bene t for this group are limited (14 16). 3.2. Avoiding Overlap and Ensuring Alignment With Existing Measure Sets and Guidelines The writing committee made every effort to avoid overlap with existing measure sets and to harmonize these Table 3. 